Convergence of Endothelial Dysfunction, Inflammation and Glucocorticoid Resistance in Depression-related Cardiovascular Diseases

Overview

Journal BMC Immunol

Publisher Biomed Central

Specialty Allergy & Immunology

Date 2024 Sep 28

PMID 39333855

Authors

Zachary Hage

Miguel M Madeira

Dimitris Koliatsis

Stella E Tsirka

Affiliations

Soon will be listed here.

Abstract

Major Depressive Disorder, or depression, has been extensively linked to dysregulated HPA axis function, chronic inflammation and cardiovascular diseases. While the former two have been studied in depth, the mechanistic connection between depression and cardiovascular disease is unclear. As major mediators of vascular homeostasis, vascular pathology and immune activity, endothelial cells represent an important player connecting the diseases. Exaggerated inflammation and glucocorticoid function are important topics to explore in the endothelial response to MDD. Glucocorticoid resistance in several cell types strongly promotes inflammatory signaling and results in worsened severity in many diseases. However, endothelial health and inflammation in chronic stress and depression are rarely considered from the perspective of glucocorticoid signaling and resistance. In this review, we aim to discuss (1) endothelial dysfunction in depression, (2) inflammation in depression, (3) general glucocorticoid resistance in depression and (4) endothelial glucocorticoid resistance in depression co-morbid inflammatory diseases. We will first describe vascular pathology, inflammation and glucocorticoid resistance separately in depression and then describe their potential interactions with one another in depression-relevant diseases. Lastly, we will hypothesize potential mechanisms by which glucocorticoid resistance in endothelial cells may contribute to vascular disease states in depressed people. Overall, endothelial-glucocorticoid signaling may play an important role in connecting depression and vascular pathology and warrants further study.

References

Sawicki C, McKim D, Wohleb E, Jarrett B, Reader B, Norden D . Social defeat promotes a reactive endothelium in a brain region-dependent manner with increased expression of key adhesion molecules, selectins and chemokines associated with the recruitment of myeloid cells to the brain. Neuroscience. 2014; 302:151-64. PMC: 4397120. DOI: 10.1016/j.neuroscience.2014.10.004. View

Shirazian S, Grant C, Aina O, Mattana J, Khorassani F, Ricardo A . Depression in Chronic Kidney Disease and End-Stage Renal Disease: Similarities and Differences in Diagnosis, Epidemiology, and Management. Kidney Int Rep. 2018; 2(1):94-107. PMC: 5720531. DOI: 10.1016/j.ekir.2016.09.005. View

Kleinschnitz C, Blecharz K, Kahles T, Schwarz T, Kraft P, Gobel K . Glucocorticoid insensitivity at the hypoxic blood-brain barrier can be reversed by inhibition of the proteasome. Stroke. 2011; 42(4):1081-9. DOI: 10.1161/STROKEAHA.110.592238. View

Dion-Albert L, Cadoret A, Doney E, Kaufmann F, Dudek K, Daigle B . Vascular and blood-brain barrier-related changes underlie stress responses and resilience in female mice and depression in human tissue. Nat Commun. 2022; 13(1):164. PMC: 8748803. DOI: 10.1038/s41467-021-27604-x. View

He Q, Liu J, Liang J, Liu X, Li W, Liu Z . Towards Improvements for Penetrating the Blood-Brain Barrier-Recent Progress from a Material and Pharmaceutical Perspective. Cells. 2018; 7(4). PMC: 5946101. DOI: 10.3390/cells7040024. View

Sagmeister M, Harper L, Hardy R . Cortisol excess in chronic kidney disease - A review of changes and impact on mortality. Front Endocrinol (Lausanne). 2023; 13:1075809. PMC: 9886668. DOI: 10.3389/fendo.2022.1075809. View

Bijata M, Baczynska E, Muller F, Bijata K, Masternak J, Krzystyniak A . Activation of the 5-HT7 receptor and MMP-9 signaling module in the hippocampal CA1 region is necessary for the development of depressive-like behavior. Cell Rep. 2022; 38(11):110532. DOI: 10.1016/j.celrep.2022.110532. View

Blecharz K, Drenckhahn D, Forster C . Glucocorticoids increase VE-cadherin expression and cause cytoskeletal rearrangements in murine brain endothelial cEND cells. J Cereb Blood Flow Metab. 2008; 28(6):1139-49. DOI: 10.1038/jcbfm.2008.2. View

Hue C, Cho F, Cao S, Dale Bass C, Meaney D, Morrison 3rd B . Dexamethasone potentiates in vitro blood-brain barrier recovery after primary blast injury by glucocorticoid receptor-mediated upregulation of ZO-1 tight junction protein. J Cereb Blood Flow Metab. 2015; 35(7):1191-8. PMC: 4640274. DOI: 10.1038/jcbfm.2015.38. View

10.

Niklasson F, Agren H . Brain energy metabolism and blood-brain barrier permeability in depressive patients: analyses of creatine, creatinine, urate, and albumin in CSF and blood. Biol Psychiatry. 1984; 19(8):1183-206. View

11.

Moncrieff J, Cooper R, Stockmann T, Amendola S, Hengartner M, Horowitz M . The serotonin theory of depression: a systematic umbrella review of the evidence. Mol Psychiatry. 2022; 28(8):3243-3256. PMC: 10618090. DOI: 10.1038/s41380-022-01661-0. View

12.

Maes M, Meltzer H, Bosmans E, Bergmans R, Vandoolaeghe E, Ranjan R . Increased plasma concentrations of interleukin-6, soluble interleukin-6, soluble interleukin-2 and transferrin receptor in major depression. J Affect Disord. 1995; 34(4):301-9. DOI: 10.1016/0165-0327(95)00028-l. View

13.

Raison C, Dantzer R, Kelley K, Lawson M, Woolwine B, Vogt G . CSF concentrations of brain tryptophan and kynurenines during immune stimulation with IFN-alpha: relationship to CNS immune responses and depression. Mol Psychiatry. 2009; 15(4):393-403. PMC: 2844942. DOI: 10.1038/mp.2009.116. View

14.

Revollo J, Cidlowski J . Mechanisms generating diversity in glucocorticoid receptor signaling. Ann N Y Acad Sci. 2009; 1179:167-78. DOI: 10.1111/j.1749-6632.2009.04986.x. View

15.

Kokkosis A, Tsirka S . Neuroimmune Mechanisms and Sex/Gender-Dependent Effects in the Pathophysiology of Mental Disorders. J Pharmacol Exp Ther. 2020; 375(1):175-192. PMC: 7569311. DOI: 10.1124/jpet.120.266163. View

16.

Gupta N, Simpkins A, Hitomi E, Dias C, Leigh R . White Matter Hyperintensity-Associated Blood-Brain Barrier Disruption and Vascular Risk Factors. J Stroke Cerebrovasc Dis. 2017; 27(2):466-471. PMC: 5808404. DOI: 10.1016/j.jstrokecerebrovasdis.2017.09.026. View

17.

RENAULT P, Hoofnagle J, Park Y, Mullen K, Peters M, Jones D . Psychiatric complications of long-term interferon alfa therapy. Arch Intern Med. 1987; 147(9):1577-80. View

18.

Omori W, Hattori K, Kajitani N, Tsuchioka M, Boku S, Kunugi H . Increased matrix metalloproteinases in cerebrospinal fluids of patients with major depressive disorder and schizophrenia. Int J Neuropsychopharmacol. 2020; . PMC: 7745248. DOI: 10.1093/ijnp/pyaa049. View

19.

Geraets A, van Agtmaal M, Stehouwer C, Sorensen B, Berendschot T, Webers C . Association of Markers of Microvascular Dysfunction With Prevalent and Incident Depressive Symptoms: The Maastricht Study. Hypertension. 2020; 76(2):342-349. DOI: 10.1161/HYPERTENSIONAHA.120.15260. View

20.

Choi J, Ifuku M, Noda M, Guilarte T . Translocator protein (18 kDa)/peripheral benzodiazepine receptor specific ligands induce microglia functions consistent with an activated state. Glia. 2010; 59(2):219-30. PMC: 4425360. DOI: 10.1002/glia.21091. View